Recursion Pharmaceuticals, Inc.
RXRX Healthcare Biotechnology
Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024. In the quarter to June 2026, revenue fell 60.1%, EPS grew 39.0%, free cash flow fell 32.0% and total debt fell 66.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow RXRX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
551.07 | 659.98 | 747.89 | 662.97 |
+8 more quarters Free account |
Receivables |
14.39 | 13.59 | 24.65 | 21.91 | |
Other current assets |
29.32 | 24.25 | 28.57 | 29.22 | |
Total current assets |
603.46 | 709.56 | 812.85 | 714.11 | |
Property, Plant, Equpment (Net) |
89.62 | 95.81 | 103.93 | 111.71 | |
Goodwill and Intangible Assets (Total) |
443.24 | 454.24 | 472.06 | 484.39 | |
Long Term Assets (Tax, Deferred) |
0.96 | 0.96 | 0.96 | 0.96 | |
Long-term assets (Other) |
17.94 | 17.44 | 18.79 | 18.83 | |
Total non-current assets |
609.21 | 629.97 | 661.29 | 685.42 | |
Total Assets |
1,212.67 | 1,339.52 | 1,474.13 | 1,399.53 | |
Notes Payable |
9.44 | — | 9.09 | 8.92 | |
Accounts Payable |
12.67 | 20.35 | 18.12 | 13.94 | |
Accrued Expenses |
56.94 | 54.21 | 70.23 | 73.36 | |
Other current liabilities |
27.59 | 32.79 | 37.61 | 47.36 | |
Total current liabilities |
119.89 | 129.70 | 147.71 | 155.10 | |
Long Term Debt (Total) |
4.75 | 7.18 | 9.56 | 11.90 | |
Long Term Tax Liability (Deferred) |
18.31 | 18.28 | 23.26 | 23.31 | |
Non-current Liabilities (Other) |
115.52 | 116.75 | 116.09 | 112.23 | |
Total non-current liabilities |
177.78 | 185.05 | 195.56 | 197.48 | |
Total liabilities |
297.67 | 314.75 | 343.27 | 352.58 | |
Additional Paid In Capital |
3,211.52 | 3,191.61 | 3,170.15 | 2,980.73 | |
Common Stock (Net) |
0.01 | 0.01 | 0.01 | 0.01 | |
Retained Earnings |
(2,324.51) | (2,193.51) | (2,076.00) | (1,967.88) | |
Common Equity (Total) |
915.00 | 1,024.77 | 1,130.87 | 1,046.95 | |
Shareholders Equity (Total) |
915.00 | 1,024.77 | 1,130.87 | 1,046.95 | |
Shareholders Equity and Liabilities (Total) |
1,212.67 | 1,339.52 | 1,474.13 | 1,399.53 | |
Shares (Common) |
534.12 | 530.63 | 528.18 | 491.80 | |
Shareholders Equity (Tangible) |
471.76 | 570.53 | 658.80 | 562.56 | |
Net Debt |
(546.31) | (652.80) | (738.32) | (651.07) | |
Total Debt |
4.75 | 7.18 | 9.56 | 11.90 |